[Clinical Effects of Different Chemotherapeutic Regimens on the Patients with Multiple Myeloma]

To explore the clinical effects of T-VD regimen (bortezomib+dexamethasone+thalidomid) and T-VAD regimen (vincristine+adriamycin+dexamethasone+thalidomide) on the patients with multiple myeloma(MM).

Thirty cases of MM treated by T-VD(T-VD group) and 30 cases of MM treated by T-VAD(T-VAD group) from April 2010 to April 2012 were included in this study. The clinical effects and long-term survival were compared betwwen these 2 groups.

Both the CR and ORR in T-VD group were higher than those in T-VAD group(P<0.05); the ORR of the non-light and light chain type in T-VD group was higher than that in the T-VAD group(P<0.05); the ORR was not different between the no-light chain type and light chain type in T-VD group(P>0.05); the ORR was not different between the non-light and light chain type of T-VAD group(P>0.05); the ORR was not different between the stage I-II of T-VD group and T-VAD group(P>0.05); the ORR for the stages of III T-VD group was higher than that of T-VAD group(P<0.05); the ORR was not different between the I-II and III stages in the T-VD group(P>0.05); The ORR for the I-II stages of control group were higher than that of the III stages(P<0.05); the levels of serum M protein, myeloma cells, β2-MG in the T-VD group were lower than those in T-VAD group(P<0.05). The rate of leukocyteopenia, nausea and vomit, weakness in T-VD group were significantly higher than those in T-VAD group(P<0.05); The incidences of infection and peripheral neuropathy in T-VD group were higher than those in T-VAD group(P<0.05).

The effect of T-VD regimen on the patients with MM is better than that of T-VAD regimen and its effect is not influenced by the clinical classification and stages, but will aggravate some side effects, thus this chemotherapeutic regimen need to be carefully chosen.